Cited by 270Epilepsy research and treatmentTraumatic Brain Injury and Neurovascular DisturbancesBarrier Structure and Function Studies

Losartan prevents acquired epilepsy via TGF‐β signaling suppression

Open access
Bar‐Klein, Guy, Cacheaux, Luisa P., Kamintsky, Lyn, Prager, Ofer, Weissberg, Itai, Schoknecht, Karl, Cheng, Paul, Kim, Soo Young +4 more·2014·Annals of Neurology

Abstract

Objective: Acquired epilepsy is frequently associated with structural lesions after trauma, stroke, and infections. Although seizures are often difficult to treat, there is no clinically applicable strategy to prevent the development of epilepsy in patients at risk. We have recently shown that vascular injury is associated with activation of albumin‐mediated transforming growth factor β (TGF‐β) signaling, and followed by local inflammatory response and epileptiform activity ex vivo. Here we investigated albumin‐mediated TGF‐β signaling and tested the efficacy of blocking the TGF‐β pathway in preventing epilepsy. Methods: We addressed the role of TGF‐β signaling in epileptogenesis in 2 different rat models of vascular injury, combining in vitro and in vivo biochemical assays, gene expression, and magnetic resonance and direct optical imaging for blood–brain barrier permeability and vascular reactivity. Long‐term electrocorticographic recordings were acquired in freely behaving animals. Results: We demonstrate that serum‐derived albumin preferentially induces activation of the activin receptor‐like kinase 5 pathway of TGF‐β receptor I in astrocytes. We further show that the angiotensin II type 1 receptor antagonist, losartan, previously identified as a blocker of peripheral TGF‐β signaling, effectively blocks albumin‐induced TGF‐β activation in the brain. Most importantly, losartan prevents the development of delayed recurrent spontaneous seizures, an effect that persists weeks after drug withdrawal. Interpretation: TGF‐β signaling, activated in astrocytes by serum‐derived albumin, is involved in epileptogenesis. We propose losartan, a drug approved by the US Food and Drug Administration, as an efficient antiepileptogenic therapy for epilepsy associated with vascular injury. Ann Neurol 2014;75:864–875

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ana.24147

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In vivo pharmacological blockade of TGFβRI/II using SB431542 and losartan decreases Smad2/3 signaling in the peri-infarct tissue during the period of GDF activity after stroke.

    “Furthermore, in vivo pharmacological blockade of TGFβRI/II using SB431542 and losartan19,20 decreases Smad2/3 signaling in the peri-infarct tissue (Supplementary Fig. 5) during the period of GDF activity after stroke.”

    From GDF10 is a signal for axonal sprouting and functional recovery after stroke (2015) · cites this paper as [19]

    The Results section on local losartan application reports that losartan significantly blocked an albumin-induced increase in cortical p-Smad2/3 in vivo. The Results section on Smad phosphorylation reports an effect of SB431542 only in cultured astrocytes. This paper does not establish that either drug reduced Smad2/3 signaling in peri-infarct tissue during GDF activity after stroke; the citing sentence points to its own Supplementary Fig. 5 for that observation. (LLM, conf=0.87)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. [3]Shinnar S Berg AT O’Dell C Predictors of multiple seizures in a cohort of children prospectively followed from the time of their first unprovoked seizure. [Internet] Ann Neurol 2000 48 2 122 123 Available from: http://www.ncbi.nlm.nih.gov/pubmed/11261451 10939563
  2. [26]Becker AJ Pitsch J Sochivko D Transcriptional upregulation of Cav3.2 mediates epileptogenesis in the pilocarpine model of epilepsy J Neurosci 2008 28 49 13341 53 19052226 PMC6671595

Cited by

Sorted by citations

Authors
Bar‐Klein, G., Cacheaux, L. P., Kamintsky, L., Prager, O., Weissberg, I., Schoknecht, K., Cheng, P., Kim, S. Y., Wood, L., Heinemann, U., Kaufer, D., & Friedman, A.
Affiliations
  • Ben-Gurion University of the Negev (IL)
  • University of California, Berkeley (US)
  • Departments of Physiology and Cell Biology Cognitive and Brain Sciences, Zlotowski Center for Neuroscience, Ben‐Gurion University of the Negev Beer‐Sheva Israel
  • Charité – Universitätsmedizin Berlin (DE)
  • Helen Wills Neuroscience Institute and Department of Integrative Biology University of California, Berkeley Berkeley CA
Corresponding author
Friedman, Alon
Venue
Annals of Neurology
Publisher
Wiley
Published
2014-05-28
Volume
75
Issue
6
Pages
864-875
ISSN
  • 0364-5134 (ISSN-L)
  • 1531-8249
OpenAlex
W1746603715
Cited by
270
References
63
Citations by year
2026: 18 · 2025: 11 · 2024: 28 · 2023: 24 · 2022: 23 · 2021: 26 · 2020: 29 · 2019: 30 · 2018: 15 · 2017: 26 · 2016: 17 · 2015: 13 · 2014: 10
FWCI
16.78
Type
journal article
Language
en
Open access
Locations
  • Annals of Neurology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health (RO1/NINDS NS066005)
  • United States - Israel Binational Science Foundation (2007185)
  • Israel Science Foundation (713/11)
  • The European Unions Seventh Framework Program (FP7/2007-2013), EPITARGET (602102)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Epilepsy research and treatment
  • Health Sciences › Medicine › Neurology › Traumatic Brain Injury and Neurovascular Disturbances
  • Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
Keywords
losartan, acquired epilepsy, epileptogenesis, TGF-beta signaling, serum albumin, vascular injury, angiotensin II type 1 receptor, ALK5, astrocytes, blood-brain barrier permeability, vascular reactivity, antiepileptogenic therapy, spontaneous seizures, electrocorticography
MeSH terms
Animals, Animals, Newborn, Anticonvulsants, Astrocytes, Benzamides, Blood-Brain Barrier, Cells, Cultured, Cerebral Cortex, Dioxoles, Disease Models, Animal, Embryo, Mammalian, Endocytosis, Epilepsy, Male, Neurons, Phosphopyruvate Hydratase, Signal Transduction, Transforming Growth Factor beta, Rats, Wistar, Losartan, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review